Does golimumab extend the spectrum of anti-TNFα inhibitors for inflammatory bowel diseases?

Abstract

Golimumab is a new drug which belongs to class of anti-TNFα inhibitors. This drug was prepared dueto unique synthesis from hybridoma cells lines which were derived from transgenic mouse. The specific golimumab synthesis granted its human origin and some favourable pharmacological properties. In PURSUIT study has been shown that golimumab is very effective therapy and induces and maintains a clinical response, clinical remission, mucosal healing and improves the quality of life in patients with moderately to severely active ulcerative colitis. The position of golimumab in clinical practice in patients with ulcerative colitis has to be proved in the next clinical studies.